Theranostic & Prognosis
Affichem has opted for a two-stage strategy:-
firstly, it will build on the discovery of its biomarker by immediately developing marketable tools for the pharmaceutical R&D market.
-
secondly, it will develop a series of diagnostic kits for several cancers to out license to a diagnostics market leader.